Introduction
The quinolone BMS-284756 (T-3811ME), identified by Toyama Chemical Co., lacks the classical C-6 fluorine of fluoroquinolones but has fluorine incorporated through a C-8 difluoromethyl ether linkage. 1 This novel des-F(6)-quinolone is now in late-stage clinical development by Bristol-Myers Squibb and Toyama Chemical Co. BMS-284756 has a broad spectrum of antibacterial activity, including good activity against anaerobes, exceptional activity against Gram-positive bacteria and the potential to cover quinolone-resistant pathogens in the clinic.
2-5 BMS-284756 has also demonstrated in vivo efficacy in an experimental model of systemic infection with a Staphylococcus aureus topoisomerase mutant strain and a model of experimental pneumonia with a penicillin-resistant Streptococcus pneumoniae strain. 2 The evaluation of over 10 000 quinolone derivatives following the introduction of nalidixic acid in 1962 has resulted in thorough knowledge of the structure-activity relationship (SAR) for many quinolone substituents. 6, 7 The first quinolones contained a bicyclic aromatic core in which a pyridone is essential for antibacterial activity. 6 These quinolones exhibited moderate Gram-negative activity and were used in the clinic to treat urinary tract infections. 8, 9 The addition of a piperazine ring at C-7 resulted in an increase in Gram-negative activity and oral absorption. 10, 11 Norfloxacin was the first of the quinolones to have the C-6 fluorine that increased quinolone activity and cell penetration.
12 Further modifications at the N-1, C-7 and C-8 positions yielded S. aureus activity as well as activity against S. pneumoniae and anaerobes. 6 In the 7-piperazine-substituted quinolones, the retention of the fluorine atom at position C-6 was found to increase dramatically both potency (DNA gyrase inhibition) and antibacterial activity. 13 Thus, most currently marketed fluoroquinolones have maintained the C-6 fluorine substituent, e.g. levofloxacin. 14, 15 Certain preclinical quino-
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lones without the C-6 fluorine exhibit overall antibacterial activity, but a fluorine at C-8 is required for good Grampositive activity for these quinolones. 16 The recent innovation of an N-cyclopropyl-4-quinolone with a C-7 isoindolin-5-yl substituent by Toyama Chemical Co., BMS-284756, indicates that presence of the C-6 fluorine is not essential for increased potency or antibacterial activity. 1 In order to characterize the target specificity and to determine the initial SAR of BMS-284756, analogues of BMS-284756 were synthesized by Toyama Chemical Co. BMS-340281 is the S-stereoisomer of BMS-284756, while BMS-340280 is the C-6 fluorinated counterpart to BMS-284756. Modifications around the C-8 position include removal of the difluoromethyl ether (BMS-340278) and replacement of this group with a methoxy group (BMS-433366). The various BMS-284756 analogues were tested for antibacterial activity and inhibition of bacterial and mammalian enzymes using an Escherichia coli DNA gyrase supercoiling assay, a S. aureus topoisomerase IV decatenation assay, a human topoisomerase II (hTopo II) relaxation assay and a cellular cytotoxicity assay.
Materials and methods

Chemicals
BMS-284756 and BMS-284756 analogues were obtained from Toyama Chemical Company (Toyama, Japan). Ciprofloxacin was obtained from Bayer Corporation (West Haven, CT, USA). Levofloxacin was obtained from OrthoMcNeil Pharmaceutical (Raritan, NJ, USA) or was extracted from tablets. Levofloxacin was extracted from 500 mg commercial tablets, purified by recrystallization, and determined to be Ͼ99.9% pure by high-pressure liquid chromatography (HPLC) analysis. Moxifloxacin was extracted from 400 mg commercial tablets, purified by recrystallization, and determined to be Ͼ99.9% pure by HPLC analysis. Compounds were solubilized in sterile water and stored at -80ЊC, except for the hTopo II assay and cytotoxicity assays in which compounds were solubilized in 0.1 M NaOH in order to achieve higher stock drug concentrations.
Preparation of relaxed DNA substrate for the DNA gyrase supercoiling inhibition assay pBR322 DNA (Promega, Madison, WI, USA) was relaxed for 2 h at 37ЊC with 13 U of topoisomerase I (Promega, Madison, WI, USA) per microgram of DNA in a 50 mM Tris-HCl pH 7.5 buffer containing 0.1 mM EDTA, 1 mM dithiothreitol (DTT), 50% (v/v) glycerol and 50 mM NaCl. The DNA was purified from the DNA/topoisomerase I mixture using a QIAquick spin column (Qiagen Inc., Chatsworth, CA, USA) to remove the topoisomerase, and the DNA was resuspended in 10 mM Tris-HCl pH 8.0.
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Expression and purification of topoisomerases
The subunits of DNA gyrase, GyrA and GyrB, were purified from E. coli overexpression constructs obtained from M. Gellert (National Institutes of Health in Bethesda, MD, USA) according to the methods of Mizuuchi et al. 17 One unit of DNA supercoiling or cleavable complex activity was defined as the amount that completely converts the DNA to supercoiled DNA in 30 min at 37ЊC. S. aureus GrlA and GrlB proteins were cloned and purified as fusion proteins of maltose-binding protein (MBP) according to the method of Tanaka et al. 18 
E. coli DNA gyrase assay
The assay was performed according to the methods of Mizuuchi et al. 17 and others: 19 0.3 g of relaxed pBR322 were incubated with 1 U of E. coli DNA gyrase for 30 min at 37ЊC in 30 L of 35 mM Tris-HCl pH 7.5 containing 1.4 mM ATP, 1.8 mM spermidine, 5 mM DTT, 0.14 mM EDTA, 6.5% glycerol, 24 mM KCl, 4 mM MgCl 2 and 0.36 mg/L of molecular grade bovine serum albumin (BSA). Serial dilutions of each quinolone were added to the above reaction mix for 50% inhibition (IC 50 ) determinations. Reactions were stopped with 15 L of 0.5% SDS containing 6 mM EDTA, 5.35% glycerol, and 0.013% bromophenol blue. Supercoiled and relaxed forms of pBR322 were separated by agarose gel electrophoresis. The DNA was visualized following staining with 0.5 mg/L of ethidium bromide. The fluorescence was visualized and quantified for IC 50 determinations using an AlphaImager 2200 system (AlphaInnotech Corporation, San Leandro, CA, USA).
S. aureus topoisomerase IV decatenation assay
The decatenation of kinetoplast DNA (kDNA) (Topogen Inc., Columbus, OH, USA) was measured using assay conditions as defined by Tanaka et al. 18 Each reaction contained 0.4 g of kDNA in a 50 mM Tris pH 8.0 buffer containing 120 mM KCl, 10 mM MgCl 2 , 0.5 mM ATP, 0.5 mM DTT and 30 mg/L of BSA and was incubated at 37ЊC for 60 min. Minimal differences in decatenation activity were noted between MBP-fusion topoisomerase IV and cleaved topoisomerase IV as measured in control experiments in the absence of quinolone. One unit of MBP-fusion topoisomerase IV activity was determined to be the amount of subunits which completely converted all catenated DNA to decatenated DNA in 30 min at 37ЊC. 
Human topoisomerase II assay
Cytotoxicity assay
Cellular cytotoxicity was measured by a colorimetric assay that makes use of the tetrazolium salt, MTS. 20 A suspension of human HeLa (ATCC no. CCL2) or HEp-2 cells (ATCC no. CCL23) was prepared at a density of 10 ϫ 10 3 cells/mL in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS) (Life Technologies, Gaithersburg, MD, USA) or 5 ϫ 10 3 cells/mL in DMEM containing 10% FCS, respectively. Cells were incubated under 5% CO 2 at 37ЊC for 3-4 h before addition of quinolone to allow adherence of cells to the 96-well plate. Compounds were assayed in duplicate and prepared as a 100ϫ stock solution at 40 mM in 0.1 M NaOH. Following the addition of serial dilutions (400-0.18 M) of quinolone to adhered cells, the plates were incubated for 48 h at 37ЊC. The cells were then washed once with medium, and 100 L of 0.6 mM MTS/0.02 mM PMS in DMEM with 10% FBS was added. Cells plated with quinolone and tetrazolium salt were incubated under 5% CO 2 at 37ЊC for 1 h and read in a SpectraMAX 320 plate reader (Molecular Devices, Sunnyvale, CA, USA) at 490 nm. CC 50 values were calculated by comparing the OD values of the compound containing samples with the vehicle controls.
Antibiotic susceptibility testing
MICs were determined by the broth microdilution technique according to the NCCLS approved guidelines. 21 The MIC was defined as the lowest concentration of antimicrobial agent that prevented visible growth at 24 h.
Results
The activities of analogues were compared in order to determine the importance of the C-6 fluorine substitution, the C-8 methoxy substitution and the stereoisomerization of BMS-284756 ( Figure 1 analogues against Gram-negative and -positive wild-type and resistant bacteria were equivalent to or within two-fold of the MICs of BMS-284756 (Table I) . BMS-284756 was active against all clinical strains tested including those with single or multiple mutations in topoisomerases. In particular, against resistant S. aureus strains A27223, A29449 and A29448, and S. pneumoniae strains A29415 and A29416, BMS-284756 and its analogues had the lowest MICs and were more active than the comparators (Table I) . The inhibition of DNA gyrase by the quinolones was measured using an E. coli DNA gyrase supercoiling inhibition assay (SCIA) (Figure 2 and Table II ). The IC 50 s of BMS-284756 and BMS-284756 analogues were indistinguishable with values ranging from 0.17 to 0.32 mg/L. The inhibition of DNA gyrase by BMS-284756 and its analogues was also comparable to ciprofloxacin, levofloxacin and moxifloxacin.
Inhibition of S. aureus topoisomerase IV decatenation activity by all quinolones was measured as shown in Table II . BMS-284756, BMS-340278 and ciprofloxacin had the lowest IC 50 s while levofloxacin had the least inhibition of enzymatic activity with an IC 50 value of 13.7 mg/L. BMS-340280 and BMS-340281 were similar to moxifloxacin with moderate topoisomerase IV inhibition.
The selectivities between bacterial and human topoisomerases of BMS-284756, BMS-284756 analogues and quinolone comparators were determined by monitoring their inhibition of relaxation activity of recombinant hTopo II (Table II) . BMS-340278 and BMS-340280 had the greatest inhibition of hTopo II with IC 50 s of 89.2 and 128.1 mg/L, respectively, distinguishing them from BMS-284756 and the other BMS-284756 analogues which had IC 50 s of 463-1131 mg/L. BMS-340281, BMS-284756 and the comparator quinolones had selectivity ratios of human/E. coli topoisomerase IC 50 s of Ͼ3000, suggesting that inhibition of human enzymes at clinically achievable concentrations would not be relevant for these compounds.
Similar to hTopo II inhibition, BMS-340278 and BMS-340280 had significant cytotoxicity as determined by the measurement of CC 50 s in the MTS cytotoxicity assay of HEp-2 cells (Table II) . BMS-433366 had a CC 50 of 136 mg/L against HEp-2 cells, which was comparable to the CC 50 of ciprofloxacin. The remainder of the compounds, including BMS-284756, had no inhibition at the highest soluble concentration tested. BMS-284756, BMS-340281, levofloxacin and moxifloxacin were the least cytotoxic quinolones tested. Similar cytotoxicity results were observed for all quinolones when tested against the HeLa cells. However, BMS-340280 was less cytotoxic in HeLa cells.
Discussion
In vitro testing demonstrated that BMS-284756 has excellent activity against resistant strains of bacteria with multiple topoisomerase mutations and bacterial enzymatic targets. Likewise, all analogues of BMS-284756 were almost equivalent in terms of activity, indicating little difference in intrinsic inhibition against both bacterial targets. Thus, although there is a significant change in removal of the C-6 fluorine, BMS-284756 and BMS-340280 exhibited similar target activity to other quinolones, inhibiting both DNA gyrase and topoisomerase IV from E. coli and S. aureus, respectively. BMS-284756 is highly selective towards bacterial topoisomerases with little activity against the mammalian homologue topoisomerase. However, removal of the C-8 difluoromethyl ether linkage (BMS-340278) or replacement of the C-8 difluoromethyl ether linkage with a methoxy group (BMS-433366) decreased target selectivity, as measured by the MTS cytotoxicity assay or hTopo II assay. The methoxy derivative also demonstrated reduced antibacterial activity against S. pneumoniae. Although the addition of the C-6 fluorine to BMS-284756 (BMS-340280) did not increase or decrease in vitro inhibition of the targets, it did result in increased inhibition of hTopo II and increased mammalian cellular toxicity. BMS-284756 as a des-fluoroquinolone does not follow the traditional SAR of recent fluoroquinolones, which required the C-6 fluorine for enhanced potency and antibacterial activity. With extremely potent activity against resistant Gram-positive organisms, BMS-284756 may be a useful addition in the clinic for the treatment of respiratory diseases and complicated skin and surgical infections. 
